Genmab
GMAB
Market cap $13.8B

22.42 USD

-0.18

0.80%

Updated Jul 30, 11:54 AM EDT

1 day

-0.80%

5 days

-4.84%

1 month

8.52%

3 months

6.00%

6 months

13.18%

Year to date

6.76%

1 year

-20.52%

5 years

-35.98%

10 years

23.32%

About: Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Employees: 2,638

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

63% more call options, than puts

Call options by funds: $15.4M | Put options by funds: $9.44M

38% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 66

6.19% more ownership

Funds ownership: 91.83% [Q4 2024] → 98.02% (+6.19%) [Q1 2025]

1% more capital invested

Capital invested by funds: $1.27B [Q4 2024] → $1.28B (+$10.5M) [Q1 2025]

8% less first-time investments, than exits

New positions opened: 37 | Existing positions closed: 40

4% less funds holding

Funds holding: 227 [Q4 2024] → 218 (-9) [Q1 2025]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$46

105%

upside

Avg. target

$46

105%

upside

High target

$46

105%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Truist Securities

Asthika Goonewardene

105%upside

$46

Buy

Maintained

8 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about GMAB published over the past 30 days

Zacks Investment Research

Genmab (GMAB) Upgraded to Strong Buy: Here's Why

Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Genmab (GMAB) Upgraded to Strong Buy: Here's Why

Zacks Investment Research

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Company Announcement Net sales of DARZALEX ® in the second quarter of 2025 totaled USD 3,539 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; July 16, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab and hyaluronidase-fihj , sold under the tradename DARZALEX FASPRO ® in the U.S. ) , as reported by J&J were USD 3,539 million in the second quarter of 2025. Net trade sales were USD 2,017 million in the U.S. and USD 1,521 million in the rest of the world.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025

Genmab Announces Changes to its Executive Committee

Media Release COPENHAGEN, Denmark; July 1, 2025 Birgitte Stephensen, Executive Vice President and Chief Legal Officer to retire after 23 years with Genmab A/S Greg Mueller joins as new Executive Vice President, General Counsel and Chief Legal Officer, effective July 1 Genmab A/S (Nasdaq: GMAB ) a nnounced today that Birgitte Stephensen, Executive Vice President and Chief Legal Officer, will retire from Genmab after a successful tenure that spanned 23 years with the company. Greg Mueller joins Genmab A/S as Executive Vice President, General Counsel and Chief Legal Officer effective July 1.

Genmab Announces Changes to its Executive Committee

Completion of Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 30, 2025 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on June 26, 2025. On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Completion of Share Buy-back Program

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

Genmab A/S is a high-margin, royalty-driven biotech with a robust pipeline and strong partnerships, notably with J&J, AbbVie, and Pfizer. Darzalex remains the key revenue driver, but patent protection and new indications should sustain growth for at least four more years. The company boasts a rock-solid balance sheet, undervalued metrics (low PE, PEG, high FCF yield), and active share buybacks.

Genmab: This Is Anything But A Value Trap, Yet It Is Currently Priced As One

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 23, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Transactions in Connection with Share Buy-back Program

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others.

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; June 17, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Transactions in Connection with Share Buy-back Program

Company Announcement COPENHAGEN, Denmark; June 16, 2025 – Genmab A/S (Nasdaq: GMAB). On March 25, 2025, Genmab announced the initiation of a share buy-back program to repurchase up to 2.2 million shares to reduce capital and to honor our commitments under the Restricted Stock Unit program.

Transactions in Connection with Share Buy-back Program

See News Rankings

Charts implemented using Lightweight Charts™